(Q41593651)

English

Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies

scientific article published on 9 March 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 October 2017

Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies (English)

1 reference

Europe PubMed Central

4 October 2017

1 reference

based on heuristic

inferred from title

Efstathios Kastritis

object named as

Efstathios Kastritis

1

0 references

Athanasios Dimopoulos

object named as

Meletios A Dimopoulos

13

0 references

Maria Gavriatopoulou

3

object named as

Maria Gavriatopoulou

1 reference

Europe PubMed Central

4 October 2017

Evangelos Terpos

12

object named as

Evangelos Terpos

1 reference

Europe PubMed Central

4 October 2017

Magdalini Migkou

4

object named as

Magdalini Migkou

1 reference

Europe PubMed Central

4 October 2017

2

object named as

Maria Roussou

1 reference

Europe PubMed Central

4 October 2017

Erasmia Psimenou

9

object named as

Erasmia Psimenou

1 reference

Europe PubMed Central

4 October 2017

Savvas Toumanidis

10

object named as

Savvas T Toumanidis

1 reference

Europe PubMed Central

4 October 2017

Argyrios Ntalianis

8

object named as

Argyrios Ntalianis

1 reference

Europe PubMed Central

4 October 2017

11

object named as

Anna Tasidou

1 reference

Europe PubMed Central

4 October 2017

author name string

Despina Kalapanida

5

1 reference

Europe PubMed Central

4 October 2017

Constantinos Pamboucas

6

1 reference

Europe PubMed Central

4 October 2017

Elisavet Kaldara

7

1 reference

Europe PubMed Central

4 October 2017

publication date

9 March 2015

1 reference

Europe PubMed Central

4 October 2017

American Journal of Hematology

1 reference

Europe PubMed Central

4 October 2017

90

1 reference

Europe PubMed Central

4 October 2017

4

1 reference

Europe PubMed Central

4 October 2017

E60-5

1 reference

Europe PubMed Central

4 October 2017

How I treat amyloidosis

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Amyloidosis: pathogenesis and new therapeutic options.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL).

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Autologous stem cell transplantation for primary systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Bortezomib in the treatment of AL amyloidosis: targeted therapy?

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patients

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23936

21 January 2018

Identifiers

10.1002/AJH.23936

1 reference

Europe PubMed Central

4 October 2017

1 reference

Europe PubMed Central

4 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41593651&oldid=1924815276"